Standardised incidence ratios (SIRs) and 95% CIs in US renal transplant recipients compared with the US general population
| SLE | Non-SLE | |||||
|---|---|---|---|---|---|---|
| Cancer type | Observed cases* | Expected cases* | SIR (95% CI) | Observed cases* | Expected cases* | SIR (95% CI) |
| All cancers | 1622 | 466 | 3.5 (2.1 to 5.7) | 1739 | 469 | 3.7 (2.4 to 5.7) |
| Lip/oropharyngeal | 791 | 11 | 72 (57.3 to 92.0) | 665 | 11 | 60.4 (36.2 to 80.1) |
| Kaposi | 38 | 1 | 38 (35.2 to 141.1) | 42 | 1 | 42 (55.2 to 89.9) |
| Neuroendocrine | 163 | 5 | 32.6 (30.7 to 50.2) | 74 | 5 | 14.8 (11.3 to 58.2) |
| Thyroid | 283 | 10 | 28.3 (16.2 to 41.2) | 238 | 10 | 23.8.5 (14.6 to 38.5) |
| Renal | 217 | 14 | 15.5 (12.3 to 21.7) | 142 | 14 | 10.1 (7.6 to 12.6) |
| Cervical | 133 | 8 | 16.6 (3.0 to 27.3) | 144 | 9 | 16.7 (11.7 to 21.6) |
| Lymphoma | 293 | 22 | 13.3 (9.0 to 14.6) | 194 | 22 | 9.0 (7.4 to 10.5) |
| Liver | 40 | 6 | 6.6 (5.5 to 7.3) | 17 | 7 | 9.0 (7.4 to 10.5) |
| Colorectal | 222 | 49 | 4.5 (3.2 to 6.1) | 150 | 50 | 2.8 (2.2 to 3.4) |
| Ovarian | 32 | 13 | 2.4 (1.3 to 5.6) | 17 | 13 | 1.3 (0.7 to 1.8) |
| Melanoma | 27 | 20 | 1.4 (1.6 to 2.8) | 22 | 20 | 1.1 (0.7 to 1.3) |
| Breast | 255 | 127 | 2.0 (1.1 to 3.1) | 280 | 127 | 2.1 (1.3 to 2.8) |
| Lung | 43 | 65 | 0.7 (0.6 to 1.0) | 90 | 64 | 1.4 (1.0 to 1.7) |
| Prostate | 54 | 163 | 0.33 (0.01 to 1.0) | 65 | 163 | 0.4 (0.2 to 0.5) |
*Observed and expected cases reported per 100 000 person-years.
SLE, systemic lupus erythematosus.